https://ephemerisx.com/research/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/concepts/2026-09-29T22:04:54+00:00 https://ephemerisx.com/research/methodology/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/concepts/facility-inspections/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/3m-health-care-infection-prevention-division/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/abbvie/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/acacia-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/accord-biopharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/accord-healthcare/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/acelrx-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/acer-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/achieve-life-sciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/actavis-an-indirect-wholly-owned-subsidiary-teva-pharmaceuti/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/adamis-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/adello-biologics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/aft-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/agile-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/akeso-biopharma/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/companies/althera-life-sciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/amgen/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/amryt-pharmaceuticals-dac/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/antares-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/aop-orphan-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/applied-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ardelyx/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/armstrong-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ars-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ascelia-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/astellas-pharma-us/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/astrazeneca/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/aveo-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/azurity-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/b-braun-medical/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/bayer-healthcare/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/belcher-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/bendarx-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/bio-thera-solutions/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/biohaven-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/bioprojet-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/braeburn/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/braeburn-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/braintree-laboratories/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/bridge-regulatory-affairs/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/bristol-myers-squibb/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/cadence-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/camargo-pharmaceutical-services/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/celitrion/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/celltrion/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/checkpoint-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/chelsea-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/chiesi-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/clarus-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/clearside-biomedical/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/cmp-development/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/coherus-biosciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/conjupro-biotherapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/coopersurgical/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/corcept-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/corium/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/csl-behring/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/cyclomedica-australia/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/daiichi-sankyo/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/delcath-systems/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/dow-pharmaceutical-sciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/dr-reddys-laboratories/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/durect/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/elc-group/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/elevar-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/eli-lilly/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/emd-serono/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/esteve-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/evergreen-theragnostics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/evofem/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/evoke-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/evolus/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/eyenovia/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/fabre-kramer-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/feinstein-institute-for-medical-research/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/fera-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ferring-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/fidelity-biopharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/fresenius-kabi-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/galephar-pharmaceutical-research/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/geno/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/genzyme/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/companies/gilead-sciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/glaxosmithkline/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/heritage-pharmaceuticals-d-b-a-avet-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/hikma-pharmaceuticals-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/hospira/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/hq-specialty-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/hugel/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/immunomedics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/impax-laboratories/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ingenus-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/innocoll-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/innopharma-licensing/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/intelgenx/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/janssen-biotech/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/jiangsu-hengrui-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/kashiv-biosciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/king-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/kyowa-pharmaceutical/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/laboratorios-farmaceuticos-rovi/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/lannett-holdings/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/lib-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/lpsen-biopharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/lterum-therapeutics-us/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/lykos-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mallinckrodt-hospital-products-ip/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mallinckrodt-pharmaceuticals-ireland/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mapi-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/marius-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/medac-gesellschaft-fur-klinische-spezialpraparate-mbh/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/medicasafe/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/meitheal-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/merck/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/metacel-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/minerva-neurosciences/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mylan/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mylan-laboratories/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mylan-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/mylan-pharmaceuticals-a-viatris/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/neuroderm/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/nnopharma-licensing/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/nobelpharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/northstar-medical-radioisotopes/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/novo-nordisk/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ocuvex-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/omeros/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/organon/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/orphan-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/orphazyme-a-s/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/par-sterile-products/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/pfizer/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/companies/pfizer-ireland-pharmaceuticals/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/companies/pharmaessentia/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/pharmaxis/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/polarean/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/provention-bio/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/proximagen/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ptc-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/recordati-rare-diseases/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/recro-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/regeneron-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/resq-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ricon-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/rosemont-pharmaceuticals-holdings/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/samsung-bioepis/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sandoz/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sanofi-aventis-us/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/santen/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/saol-international-development/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sarepta-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/scilex-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/scpharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/scpharmaceuticals-services/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sedor-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/seikagaku/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sentynl-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/shandong-luye-pharmaceutical/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/shilpa-medicare/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/spes-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/stealth-biotherapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sun-pharma-advanced-research/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sun-pharma-global-fze/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sun-pharmaceutical-industries/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sunovion-pharmaceuticals/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/companies/swedish-orphan-biovitrum-publ/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/sydnexis/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/takeda-pharmaceuticals-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/tanvex-biopharma-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/telix-pharmaceuticals-us/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/teva-neuroscience/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/teva-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/teva-pharmaceuticals-usa/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/teva-womens-health/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/therakind/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/companies/thomas-chaly-phd-faic/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/trevena/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/tris-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/ugb/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/united-therapeutics/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/university-california-san-francisco/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/valeant-pharmaceuticals-ireland/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/vero-biotech/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/viiv-healthcare/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/vyluma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/xbrane-biopharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/xellia-pharmaceuticals-aps/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/xspray-pharma/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/zealand-pharma-us/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/zhejiang-novus-pharmaceuticals/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/companies/zydus-worldwide-dmcc/2026-09-29T22:49:56+00:00 https://ephemerisx.com/research/drugs/2026-09-30T00:00:04+00:00 https://ephemerisx.com/research/drugs/aducanumab-bla761178/2026-09-30T00:50:37+00:00 https://ephemerisx.com/research/drugs/bupropion-naltrexone-nda200063/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/donanemab-bla761248/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/dulaglutide-bla125469/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/exenatide-nda209210/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/insulin-liraglutide-bla208583/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/insulin-lixisenatide-bla208673/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/lecanemab-bla761269/2026-09-30T00:50:37+00:00 https://ephemerisx.com/research/drugs/liraglutide-nda206321/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/lixisenatide-bla208471/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/orforglipron-nda220934/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/phentermine-topiramate-nda22580/2026-09-30T00:50:37+00:00 https://ephemerisx.com/research/drugs/semaglutide-nda209637/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/semaglutide-nda213051/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/semaglutide-nda213182/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/semaglutide-nda215256/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/semaglutide-nda218316/2026-09-30T00:50:37+00:00 https://ephemerisx.com/research/drugs/setmelanotide-nda213793/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/tirzepatide-nda215866/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/drugs/tirzepatide-nda217806/2026-09-30T00:53:27+00:00 https://ephemerisx.com/research/deep-research/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-the-fda-said-before-the-bla/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-the-first-fda-letter-objected-to/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/how-replimune-described-the-first-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-was-said-at-the-type-a-meeting/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-replimune-resubmitted/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-happened-to-the-confirmatory-trial/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-the-second-fda-letter-objected-to/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/why-a-different-fda-team-reviewed-the-resubmission/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-changed-between-the-fda-letters/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/how-replimune-described-the-second-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/when-did-injected-lesions-become-an-fda-concern/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/was-the-fdas-advice-consistent/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-happened-at-replimune-after-the-second-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/how-rp1-went-from-a-second-letter-to-approval/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/why-rp1-response-rates-differ/2026-10-08 https://ephemerisx.com/research/deep-research/companies/replimune/what-remains-unresolved/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/did-the-fda-agree-to-aldeyras-chamber-trial-design/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/did-the-2025-letter-repeat-the-2023-request/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/what-did-the-fda-find-wrong-with-study-030/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/did-the-second-chamber-trial-answer-the-fda/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/how-did-the-field-trial-enter-the-fdas-review/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/was-the-fda-negotiating-reproxalaps-label/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/what-changed-between-the-fdas-reproxalap-letters/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/how-many-reproxalap-trials-succeeded/2026-10-08 https://ephemerisx.com/research/deep-research/companies/aldeyra-therapeutics/what-is-aldeyra-appealing/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/what-the-fda-first-letter-required/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/how-cormedix-described-the-first-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/what-cormedix-said-it-fixed-before-resubmitting/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/what-changed-between-the-fda-letters/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/how-cormedix-described-the-second-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/how-a-heparin-suppliers-warning-letter-held-up-defencath/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/why-the-fda-called-the-name-defencath-unacceptable/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/which-manufacturer-was-defencath-approved-with/2026-10-08 https://ephemerisx.com/research/deep-research/companies/cormedix/what-the-lawsuits-over-the-fda-letters-led-to/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/was-the-august-2025-letter-the-first/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/what-the-fdas-august-2025-letter-objected-to/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/did-the-fda-ask-for-another-trial/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/what-came-out-of-the-september-2025-meeting/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/what-changed-between-the-fda-letters/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/how-did-outlook-describe-norse-eight/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/why-do-the-letter-dates-differ/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/what-happened-after-the-second-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/outlook-therapeutics/how-did-the-same-evidence-become-substantial-evidence/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/what-the-fdas-first-letter-objected-to/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/how-did-verrica-describe-the-fdas-first-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/what-happened-to-the-glass-ampule-the-fda-flagged/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/what-human-factor-comments-came-with-the-second-letter/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/why-did-the-second-letter-turn-on-a-contract-manufacturer/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/what-changed-between-the-second-and-third-letters/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/how-did-vp-102-get-from-a-third-letter-to-approval/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/what-is-the-securities-class-action-against-verrica-about/2026-10-08 https://ephemerisx.com/research/deep-research/companies/verrica-pharmaceuticals/how-did-verricas-account-of-the-fda-letters-change/2026-10-08 https://ephemerisx.com/research/deep-research/how-it-works/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/what-happens-after-a-second-fda-letter/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/what-changed-the-outcome-without-a-new-trial/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/class-1-and-class-2-resubmissions/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/when-is-one-trial-enough/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/when-an-fda-letter-turns-on-a-contract-manufacturer/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/what-no-efficacy-or-safety-issues-means/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/connection/comparable-evidence/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/connection/divergent-outcome/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/connection/regulatory-pathway/2026-10-08 https://ephemerisx.com/research/deep-research/cross-investigations/connection/shared-concern/2026-10-08 https://ephemerisx.com/research/deep-research/investigations/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/what-did-the-fda-accept-for-papzimeos/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/how-did-papzimeos-become-a-traditional-approval/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/what-did-inovio-say-papzimeos-meant-for-ino-3107/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/what-did-the-fda-flag-when-it-accepted-ino-3107/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/what-has-inovio-disclosed-about-the-review/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/where-does-ino-3107s-confirmatory-trial-stand/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/how-do-inovio-and-precigen-describe-each-other/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/what-is-public-before-october-30-2026/2026-10-08 https://ephemerisx.com/research/deep-research/cases/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-changed-in-the-evidence-behind-jaypircas-approvals/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-supported-jaypircas-first-accelerated-approval/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-uncertainty-did-the-fda-record-in-2023/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-supported-the-cll-accelerated-approval/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-converted-the-cll-approval-to-traditional-approval/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/did-the-traditional-approval-cover-the-same-patients/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-did-the-confirmatory-trial-show-beyond-its-endpoint/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-supported-the-previously-untreated-cll-approval/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/how-do-jaypircas-four-fda-decisions-compare/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/did-the-evidence-accumulate/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/what-stayed-the-same-across-jaypircas-approvals/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/where-does-the-mantle-cell-lymphoma-confirmatory-trial-stand/2026-10-08 https://ephemerisx.com/research/deep-research/cases/jaypirca/how-did-lilly-describe-each-fda-decision/2026-10-08 https://ephemerisx.com/research/deep-research/cases/ino-3107-rrp/do-the-two-trials-measure-the-same-thing/2026-10-08 https://ephemerisx.com/research/atlas/2026-10-09